Company Dossier · Health Care
Haemonetics
- MidCap 400
What Haemonetics is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 27, 2026: $1.35 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 27, 2026: $0.29 billion, up 53% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 27, 2026: $0.04 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to March 28, 2026: $0.18 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 6, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.75 of 1.Palanor Discourse
- Guidance in the last 90 days: 2 outlook figures raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed May 20, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q4 2025: $0.1 million on the open market.SEC Form 4
- 329 institutional managers reported a position at June 30, 2026 (+5 on the quarter before).SEC Form 13F
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Haemonetics yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Haemonetics, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralHaemonetics gains after update on CSL supply deal (HAE:NYSE)
seekingalpha.com · via Marketaux · Oct 8, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Sep 15, 2026Patent
- Jul 28, 20268-KDirector or officer changeItem 5.02
- Jul 28, 20268-KShareholder vote resultsItem 5.07
- Jul 7, 2026PatentPatent granted: IMPLANT FOR VASCULAR CLOSUREUS 12672862
- Jun 30, 2026Patent
- Jun 16, 2026Patent
- May 20, 202610-KAnnual report (10-K)1 risk factors added, 0 removed
- May 5, 2026Patent
- May 1, 20268-KDirector or officer changeItem 5.02
- Jul 25, 20258-KShareholder vote resultsItem 5.07
- May 21, 202510-KAnnual report (10-K)1 risk factors added, 2 removed
- May 8, 20258-KExit or restructuring costsItem 2.05
- Mar 3, 20258-KDirector or officer changeItem 5.02
- Jan 3, 20258-KDirector or officer changeItem 5.02
- May 20, 202410-KAnnual report (10-K)1 risk factors added, 0 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| HealthEquity HQY | $1.4B | $0.5B | Jul 31, 2026 |
| Madrigal Pharmaceuticals MDGL | $1.3B | −$0.2B | Jun 30, 2026 |
| Tempus AI TEM | $1.4B | −$0.3B | Jun 30, 2026 |
| LivaNova LIVN | $1.5B | $0.1B | Jun 30, 2026 |
| Sotera Health SHC | $1.2B | $0.1B | Jun 30, 2026 |
| Bio-Techne TECH | $1.2B | $0.3B | Jun 30, 2026 |
| Penumbra, Inc. PEN | $1.5B | $0.2B | Jun 30, 2026 |
| Guardant Health GH | $1.2B | −$0.2B | Jun 30, 2026 |